NMT Logo
    • About NMT Medical
      • Who we are
      • Our History
      • Our Executive Team
      • Scientific Advisory Board
      • Careers
        • Career Opportunities
        • Application for Employment
      • Directions
    • Structural Heart Repair
      • Patent Foramen Ovale
      • Atrial Septal Defect
      • Ventricular Septal Defect
      • FDA Disclaimer
    • NMT Technology
      • Technology Overview
      • Clinical History
      • BioSTAR®
        • Clinical Trials
        • Technology-Approach
      • STARFlex®
        • Clinical Trials
        • Technology Approach
      • CardioSEAL®
        • Technology Approach
    • Patient Education
      • Signs of Stroke
      • 10 Questions to ask your Doctor
      • Patient Guides
        • Brazilian Portuguese
        • Danish
        • Dutch
        • English
        • Finnish
        • French
        • German
        • Italian
        • Norwegian
        • Portuguese
        • Spanish
        • Swedish
      • Patients Videos
    • Medical Professional
      • MRI Safety
      • Presentations
      • Medical Professional Videos
      • Clinical Trials
      • Conference Calendar
      • Instructions for Use
      • Newsletter
        • 2009 clinical trial update
        • Issue 1 2009
        • Issue 2 2009
        • Issue 3 2009
        • Issue 4 2009
        • Issue 1 2010
      • Publications
    • Investors
      • Corporate Profile
      • Stock Information
        • Historic Prices
      • Press Releases
      • Event Calendar
      • Archived Webcasts
      • Presentations
      • Corporate Governance
        • Officers & Directors
        • Governance Documents
        • Committee Composition
      • Annual Reports
      • Annual Meeting and Proxy
      • Clinical Studies
      • Fact Sheet
      • SEC Filings
      • Email Notification
      • Information Request
      • FAQs
    • Contact Us
      • Contact Information
      • Contact Us Form

Investor Relations

  • Investor Relations
    • Corporate Profile
    • Stock Information
    • Press Releases
    • Event Calendar
    • Archived Webcasts
    • Presentations
    • Corporate Governance
    • Annual Reports
    • Annual Meeting and Proxy
    • Clinical Studies
    • Fact Sheet
    • SEC Filings
    • Email Notification
    • Information Request
    • FAQs

Corporate Profile

email thisPDF viewPrint view
Market SummaryDesktop Summary

Trading Symbol

NMTI
ExchangeNASDAQ
Market Value ($M)5.85
Stock Quote $ 0.45
Change  $ 0
0%
Volume394,833
As of September 3, 2010
Minimum 20 minute delay.



Press Releases
8/26/2010NMT Medical Announces Changes in Management and Board of Directors

7/29/2010NMT Medical Announces Second-Quarter 2010 Financial Results

7/15/2010NMT Medical to Release Second-Quarter 2010 Financial Results on July 29

6/17/2010NMT Medical Announces Preliminary Results of CLOSURE I PFO/Stroke Trial

5/25/2010NMT Medical Launches Rapid Transport Septal Implant Delivery System in France


Contact Information
NMT Medical, Inc.
27 Wormwood St.
Boston, MA 02210
(617)737-0930

Investor Relations
Please contact us via email at:
info@nmtmedical.com


NMT Medical (NASDAQ: NMTI) is an advanced medical technology company that designs, develops, manufactures and markets proprietary implant technologies that allow interventional cardiologists to treat structural heart disease through minimally invasive, catheter-based procedures. NMT Medical is currently investigating the potential connection between a common heart defect that allows a right to left shunt or flow of blood through a defect like a patent foramen ovale (PFO) and brain attacks such as embolic stroke, transient ischemic attacks (TIAs) and migraine headaches. A common right to left shunt can allow venous blood, unfiltered and unmanaged by the lungs, to enter the arterial circulation of the brain, possibly triggering a cerebral event or brain attack. More than 34,000 PFOs have been treated globally with NMT's minimally invasive, catheter-based implant technology. NMT Medical was founded in 1986 and is headquartered in Boston, Massachusetts.

Stroke Opportunity
PFO has been implicated as a possible risk factor of embolic stroke and TIA, for which current treatments include lifelong drug therapy or open heart surgery. NMT estimates the worldwide market for stroke- and TIA-related PFO closure procedures at 250,000 annually.






Featured ReportRecent Events


2009 Annual Report

Webcast
NMT Medical Q2 2010 Earnings Conference Call
Thursday, July 29th, 2010
9:30 AM ET



Copyright 2010, © SNL Financial LC  Terms of Use

Quick Links

Conference Calendar
Press Releases
Webcasts

family

"When you have children depend on you, migraine has a massive impact."

Liz Norwood

Learn More

 

Home | About NMT Medical | Structural Heart Repair | NMT Technology | Patient Education | Medical Professionals 
Investors | Contact Us | Privacy Policy | Glossary | Login 

All content © 2010 NMT Medical, Inc.
NMT Medical, Inc., 27 Wormwood Street, Boston, MA 02210 | 617.737.0930